

3rd International ALL Assembly
Park Inn by Radisson Amsterdam City West Hotel
Amsterdam, The Netherlands
5–6 October 2018

SPEAKERS ARE CURRENTLY NOT CONFIRMED

Co-chairs: Rupert Handgretinger (Germany) and Max Topp (Germany)

Friday 5 October 2018		
Time	Session	Speaker/Chair
12.00–13.00	Lunch	
13.00–13.10	Welcome and introduction	Jan Cornelissen (Netherlands) and Rupert Handgretinger (Germany)
Session 1	Do we have the tools for personalised therapy of ALL?	Franco Locatelli (Italy)
13.10–13.30	<ul style="list-style-type: none"> • Latest concepts in the diagnosis of genetic ALL subtypes 	Charles Mullighan (USA)
13.30–13.50	<ul style="list-style-type: none"> • Update on targeted therapies for Philadelphia-like ALL 	Stephen Hunger (USA)
13.50–14.10	<ul style="list-style-type: none"> • In vitro diagnostics 	Jean-Pierre Bourquin (Switzerland)
14.10–14.30	<ul style="list-style-type: none"> • Combining MRD quantitation and genetics in post-remission risk stratification 	John Moppett (UK)
14.30–14.50	Panel discussion	
14.50–15.20	Coffee break	
Session 2	Immunotherapy for ALL	Nicola Göckbuget (Germany)
15.20–15.40	<ul style="list-style-type: none"> • Bispecific T-cell therapy for adult ALL 	Max Topp (Germany)
15.40–16.00	<ul style="list-style-type: none"> • CAR-T cells: challenges and opportunities 	Martin Pule (UK)
16.00–16.20	<ul style="list-style-type: none"> • Novel adoptive cell therapies for ALL 	Rupert Handgretinger (Germany)
16.20–16.40	<ul style="list-style-type: none"> • Mechanisms of CD19/CD22 antigen escape 	Mascha Binder (Germany)
16.40–17.00	Panel discussion	
17.00–18.00	Special interest workshops – delegates to select ONE workshop to attend as part of registration process	
	<ul style="list-style-type: none"> • Challenges of MRD evaluation including NGS in the era of targeted agents 	Monika Brüggemann (Germany)
	<ul style="list-style-type: none"> • Optimal use of asparaginase 	Nicola Göckbuget (Germany)
	<ul style="list-style-type: none"> • Current challenges and future perspectives on allogeneic HSCT 	Jan Cornelissen (Netherlands)
	<ul style="list-style-type: none"> • Supporting ALL patients throughout their treatment pathway 	Adele Fielding (UK)
	<ul style="list-style-type: none"> • Diagnosis and management of osteonecrosis 	Kjeld Schmiegelow (Denmark)
	<ul style="list-style-type: none"> • Immunological reconstitution in patients receiving immunotherapy 	Alberto Orfao (Spain)
18.00	Informal meet the expert session	
19.00	Dinner	

Saturday 6 October 2018		
Time	Session	Speaker/Chair
09.00–09.05	Welcome and introduction to Day 2	Max Topp (Germany)
Session 3	Safety and toxicity management in ALL	Max Topp (Germany)
09.05–09.25	<ul style="list-style-type: none"> Management of toxicity with conventional chemotherapy agents 	Nicola Gökbüget (Germany)
09.25–09.45	<ul style="list-style-type: none"> Management of toxicity with antigen-targeted therapies 	Françoise Huguet (France)
09.45–10.05	<ul style="list-style-type: none"> Using genetics to predict and manage AEs associated with ALL therapy 	Mary Relling (USA)
10.05–10.20	Panel discussion	
Session 4	Paediatric ALL	R Handgretinger (Germany)
10.20–10.35	<ul style="list-style-type: none"> Can we reduce the intensity of frontline therapy? 	Rob Pieters (Netherlands)
10.35–10.50	<ul style="list-style-type: none"> Secondary malignancies following therapy for ALL? 	Kjeld Schmiegelow (Denmark)
10.50–11.05	<ul style="list-style-type: none"> Novel therapies for paediatric B-ALL 	Franco Locatelli (Italy)
11.05–11.20	Panel discussion	
11.20–11.50	Coffee break	
11.50–13.25	Interactive 'Meet the expert/How I treat' workshops 11.50–12.35 Rotation 1 12.40–13.25 Rotation 2 <i>Delegates to select TWO workshops to attend (one per rotation) as part of registration process</i>	
	<ul style="list-style-type: none"> How I treat older patients with ALL 	Hervé Dombret (France)
	<ul style="list-style-type: none"> How I treat MLL-rearranged ALL 	Rob Pieters (Netherlands)
	<ul style="list-style-type: none"> How I treat extramedullary involvement in ALL 	Dieter Hoelzer (Germany)
	<ul style="list-style-type: none"> How I treat MRD-positive ALL 	Max Topp (Germany)
	<ul style="list-style-type: none"> How I treat relapsed/refractory ALL 	Josep Ribera (Spain)
	<ul style="list-style-type: none"> How I treat T-ALL/lymphoblastic lymphoma 	Stephen Hunger (USA)
	<ul style="list-style-type: none"> How I treat adolescents and young adults with ALL 	Nicolas Boissel (France)
	<ul style="list-style-type: none"> How I transplant adult ALL patients 	Sebastian Giebel (Poland)
13.25–14.25	Lunch	
Session 5	T-cell ALL	Dieter Hoelzer (Germany)
14.25–14.40	<ul style="list-style-type: none"> Current results and challenges with conventional therapy of T-ALL 	Renato Bassan (Italy)
14.40–14.55	<ul style="list-style-type: none"> Novel therapies for T-ALL? 	Nicolas Boissel (France)
14.55–15.10	<ul style="list-style-type: none"> Management of relapsed T-ALL in children 	Josef Voormor (UK)
15.10–15.25	Panel Discussion	
Session 6	Philadelphia chromosome (Ph)-positive ALL	Hervé Dombret (France)
15.25–15.40	<ul style="list-style-type: none"> Optimal use of TKIs for therapy of Ph-positive ALL 	Josep Ribera (Spain)
15.40–16.10	Debate: <i>HSCT vs no HSCT in Ph-positive ALL?</i>	
	<ul style="list-style-type: none"> Yes 	Oliver Ottmann (UK)
	<ul style="list-style-type: none"> No 	Robin Foà (Italy)
16.10–16.25	Panel discussion	
16.25–16.40	Future horizons in ALL	Hervé Dombret (France)
16.40–16.45	Summary and close	Max Topp and Rupert Handgretinger (Germany)